MX362804B - Composiciones acuosas de capsaicinoides que comprenden un analgésico y un vehículo acuoso, y uso de las mismas para el tratamiento del dolor. - Google Patents

Composiciones acuosas de capsaicinoides que comprenden un analgésico y un vehículo acuoso, y uso de las mismas para el tratamiento del dolor.

Info

Publication number
MX362804B
MX362804B MX2015005879A MX2015005879A MX362804B MX 362804 B MX362804 B MX 362804B MX 2015005879 A MX2015005879 A MX 2015005879A MX 2015005879 A MX2015005879 A MX 2015005879A MX 362804 B MX362804 B MX 362804B
Authority
MX
Mexico
Prior art keywords
capsaicinoid
formulations
treatment
corticosteroid
administration
Prior art date
Application number
MX2015005879A
Other languages
English (en)
Other versions
MX2015005879A (es
Inventor
Daniel Bucks
Philip J Birbara
Charles A Birbara
Mary Coughlin
Original Assignee
Vizuri Health Sciences Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vizuri Health Sciences Llc filed Critical Vizuri Health Sciences Llc
Publication of MX2015005879A publication Critical patent/MX2015005879A/es
Publication of MX362804B publication Critical patent/MX362804B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/738—Cross-linked polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Abstract

En este documento se dan a conocer formulaciones de capsaicinoides y métodos de tratamiento los cuales se pueden utilizar para tratar/atenuar el dolor en mamíferos. Típicamente, la administración es por vía de una inyección en un sitio discreto para proporcionar alivio al dolor durante un período de tiempo prolongado. Las formulaciones se administran en un vehículo farmacéuticamente aceptable. Las formulaciones incluyen un agente analgésico en una cantidad suficiente para atenuar los efectos de quemadura e hiperalgésicos de la administración de capsaicinoides. La invención también incluye un método para tratar el dolor por medio de la administración de un corticosteroide seguido por la administración de un capsaicinoide.
MX2015005879A 2012-11-12 2013-11-12 Composiciones acuosas de capsaicinoides que comprenden un analgésico y un vehículo acuoso, y uso de las mismas para el tratamiento del dolor. MX362804B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261725161P 2012-11-12 2012-11-12
PCT/US2013/069711 WO2014075084A2 (en) 2012-11-12 2013-11-12 Aqueous based capsaicinoid formulations and methods of manufacture and use

Publications (2)

Publication Number Publication Date
MX2015005879A MX2015005879A (es) 2016-02-05
MX362804B true MX362804B (es) 2019-02-14

Family

ID=49880927

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015005879A MX362804B (es) 2012-11-12 2013-11-12 Composiciones acuosas de capsaicinoides que comprenden un analgésico y un vehículo acuoso, y uso de las mismas para el tratamiento del dolor.
MX2018013715A MX2018013715A (es) 2012-11-12 2015-05-11 Composiciones acuosas de capsaicinoides que comprenden un analgesico y un vehiculo acuoso, y uso de las mismas para el tratamiento del dolor.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2018013715A MX2018013715A (es) 2012-11-12 2015-05-11 Composiciones acuosas de capsaicinoides que comprenden un analgesico y un vehiculo acuoso, y uso de las mismas para el tratamiento del dolor.

Country Status (9)

Country Link
US (2) US20140142073A1 (es)
EP (2) EP2916817B1 (es)
JP (1) JP6695140B2 (es)
KR (2) KR20150084996A (es)
CN (1) CN105101949A (es)
AU (1) AU2013341380B2 (es)
CA (1) CA2891218A1 (es)
MX (2) MX362804B (es)
WO (1) WO2014075084A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150133561A1 (en) * 2013-11-12 2015-05-14 Vizuri Health Sciences Llc Aqueous based capsaicinoid formulations and methods of manufacture and use
KR102073258B1 (ko) 2014-04-15 2020-02-04 비쭈리 헬스 사이언스 엘엘씨 통증 완화용 국소 조성물, 제조방법 및 용도
JP6948762B2 (ja) * 2015-10-16 2021-10-13 株式会社マンダム Ｔｒｐｖ１活性抑制剤作用増幅用組成物
WO2017127628A1 (en) * 2016-01-22 2017-07-27 Centrexion Therapeutics Corporation Capsaicn sequential dosing method for treatment of morton's neuroma pain
US11000490B2 (en) * 2016-11-02 2021-05-11 Centrexion Therapeutics Corporation Stable aqueous capsaicin injectable formulations and medical uses thereof
CN111201015A (zh) 2017-07-20 2020-05-26 中枢疗法公司 使用辣椒素治疗疼痛的方法和组合物
WO2020041658A1 (en) * 2018-08-24 2020-02-27 Centrexion Therapeutics Corporation Capsaicin sequential dosing method for treatment of knee joint pain
CN112691091A (zh) * 2021-01-09 2021-04-23 胡宝贤 低浓度石炭酸的新应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599342A (en) * 1984-01-16 1986-07-08 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
US4702916A (en) * 1985-12-03 1987-10-27 Warner-Lambert Company Analgesic stick compositions
JPS63130540A (ja) * 1986-11-18 1988-06-02 Sunstar Inc 鎮痛用組成物
JPH0621063B2 (ja) * 1986-12-06 1994-03-23 サンスタ−株式会社 歯科用鎮痛剤組成物
ES2179473T5 (es) 1997-03-13 2006-03-01 James N. Campbell Composiciones que contienen capsaicina o analogos de capsaicina y un anestesico local.
JP3022541B1 (ja) * 1999-01-11 2000-03-21 株式会社ヘルスサイエンスセンター 外用剤
US6573302B1 (en) * 1999-09-29 2003-06-03 Medical Merchandising, Inc. Cream utilizing capsaicin
US6579543B1 (en) * 2002-02-22 2003-06-17 Jackie H. McClung Composition for topical application to skin
US20040156931A1 (en) 2002-12-18 2004-08-12 Algorx Administration of capsaicinoids
CA2510181C (en) 2002-12-18 2011-03-08 Algorx Pharmaceuticals, Inc. Administration of capsaicinoids
WO2004092122A2 (en) 2003-04-08 2004-10-28 Algorx Pharmaceuticals, Inc. Preparation and purification of synthetic capsaicin
JP5148271B2 (ja) 2004-06-02 2013-02-20 ニューロジズエックス，インコーポレーテッド 疼痛処置のためのカプサイシノイド、局所麻酔薬および／または鎮痒薬を含有する処方物
JP2006298944A (ja) * 2004-11-05 2006-11-02 Maruishi Pharmaceutical Co Ltd インスリン様成長因子−１分泌促進剤
CA2596194A1 (en) * 2004-11-24 2006-06-01 Algorx Pharmaceuticals, Inc. Capsaicinoid gel formulation and uses thereof
US20100047181A1 (en) * 2004-12-22 2010-02-25 Mestex Ag Mixture of a vanilloid receptor agonist and a substance inhibiting nerve regeneration, use thereof for producing a painkiller, and method for applying said painkiller
DK1830835T3 (da) 2004-12-28 2012-07-02 Mestex Ag Anvendelse af en vanilloid receptorantagonist sammen med et glycosaminoglycan eller proteoglycan til fremstilling af et middel til behandling af smerter
US20070098660A1 (en) * 2005-10-27 2007-05-03 Jim Taneri Methods and compositions for epilation
US8623335B2 (en) * 2007-09-10 2014-01-07 Tauna Ann Waddington Scar and rosacea and other skin care treatment composition and method
US8158682B2 (en) 2008-09-12 2012-04-17 Vallinex, Inc. Instillation administration of capsaicinoids for the treatment of pain
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
CA2792729C (en) * 2010-03-12 2016-06-28 Allergan Industrie, Sas Fluid compositions for improving skin conditions
BR112013010958A8 (pt) * 2010-10-22 2017-10-03 Api Genesis Llc Métodos para elevar a solubilidade de compostos pouco solúveis e métodos para fabricação e para uso de formulações de tais compostos
JP6228540B2 (ja) 2011-09-09 2017-11-08 ヴィズリ・ヘルス・サイエンスィズ・エルエルシー Ｔｒｐｖ１選択的アゴニストを含む疼痛軽減組成物、ならびにその製造および使用

Also Published As

Publication number Publication date
KR20200119351A (ko) 2020-10-19
MX2018013715A (es) 2019-07-29
WO2014075084A2 (en) 2014-05-15
WO2014075084A3 (en) 2014-07-10
EP2916817A2 (en) 2015-09-16
MX2015005879A (es) 2016-02-05
JP6695140B2 (ja) 2020-05-20
EP2916817B1 (en) 2018-09-12
EP3446680A1 (en) 2019-02-27
CA2891218A1 (en) 2014-05-15
AU2013341380A2 (en) 2015-10-22
US20190022110A1 (en) 2019-01-24
AU2013341380B2 (en) 2018-04-26
US20140142073A1 (en) 2014-05-22
JP2015536998A (ja) 2015-12-24
KR20150084996A (ko) 2015-07-22
AU2013341380A1 (en) 2014-05-15
CN105101949A (zh) 2015-11-25

Similar Documents

Publication Publication Date Title
MX2018013715A (es) Composiciones acuosas de capsaicinoides que comprenden un analgesico y un vehiculo acuoso, y uso de las mismas para el tratamiento del dolor.
MX2016006179A (es) Formulaciones de capsaicinoides basadas en agua y metodos de manufactura y uso.
MX2014004548A (es) Metodos para tratar pacientes pediatricos usando dexmedetomidina.
MX2016005532A (es) Metodos para usar oxido nitrico en un estado de plasma para tratar condiciones medicas y enfermedades.
MX2020004023A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
PH12014501997A1 (en) Esketamine for the treatment of treatment-refractory or treatment-resistant depression
GB2491327A (en) Delayed prolonged drug delivery
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
GB2491328A (en) Immediate/delayed drug delivery
WO2013078440A3 (en) Enhanced treatment regimens using mtor inhibitors
BR112016007946A2 (pt) combinação farmacêutica, usos da mesma, de plinabulina e de composição, kits ou mistura e método para tratar e/ou prevenir câncer
MX2010012860A (es) Metodos para tratar cancer del sistema nervioso central.
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
MX2015003035A (es) Administracion de inhibidores de acetilcolinesterasa para mitigar la paralisis inducida por neurotoxinas y el bloqueo neuromuscular residual.
MX2016002479A (es) Uso de inhibidores de acetil-coa carboxilasa para tratar acne vulgaris.
BR112015004110A2 (pt) sistemas e métodos de distribuição de drogas para tratamento de próstata
IN2014DN08598A (es)
MY187167A (en) Medical treatments based on anamorelin
MX2015016418A (es) Dihidroetorfina para proporcionar el alivio del dolor y la anestesia.
MX2020001768A (es) Metodos de tratamiento de la osteoartritis con gel de canabidiol transdermico.
MY180772A (en) Novel therapeutic mirtazapine combinations for use in pain disorders
MX2010013790A (es) Composiciones y metodos para tratar inflamacion de corneas.
TW201613599A (en) Use of composition for manufacture of medicament for suppressing androgen receptor related function and treatment of androgen receptor related disease
MX2014013491A (es) Metodos para mantener, tratar o mejorar la funcion cognitiva.
NZ760033A (en) Methods to treat opioid use disorder

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: MICROSOFT TECHNOLOGY LICENSING, LLC

FG Grant or registration